NASDAQ:SRNE Sorrento Therapeutics Q3 2022 Earnings Results & Report $0.0008 0.00 (0.00%) As of 10/9/2026 03:57 PM Eastern Sorrento Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2022 results, released November 8, 2022. The company reported EPS of -$0.20 versus the -$0.25 consensus estimate, while revenue of $17.40 million topped the $11.69 million estimate by $5.71 million. Research:Profile Earnings Announcement Details QuarterQ3 2022Report DateNovember 8, 2022 Sorrento Therapeutics EPS ResultsActual EPS-$0.20Consensus EPS -$0.25Beat/MissBeat by +$0.05One Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersSorrento Therapeutics Revenue ResultsActual Revenue$17.40 millionExpected Revenue$11.69 millionBeat/MissBeat by +$5.71 millionYoY Revenue GrowthN/AUpcoming EarningsSorrento Therapeutics' next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Sorrento Therapeutics Q3 2022 Earnings FAQ Did Sorrento Therapeutics beat earnings estimates for Q3 2022? Sorrento Therapeutics (NASDAQ:SRNE) reported earnings of -$0.20 per share for Q3 2022, beating the consensus estimate of -$0.25. The report was announced on Tuesday, November 8, 2022. What was Sorrento Therapeutics' revenue for Q3 2022? Sorrento Therapeutics reported revenue of $17.40 million for Q3 2022, against a consensus estimate of $11.69 million. When is Sorrento Therapeutics' next earnings date? Sorrento Therapeutics' next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Sorrento Therapeutics on the company's earnings history page. Sorrento Therapeutics Earnings HeadlinesSorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comSRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 11 at 1:00 AM | InvestorPlace (Ad)Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSee More Sorrento Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sorrento Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sorrento Therapeutics and other key companies, straight to your email. Email Address About Sorrento TherapeuticsSorrento Therapeutics (NASDAQ:SRNE) is a biotechnology company focused on developing therapies for cancer, chronic pain and other serious medical conditions. The company has historically pursued treatments based on antibody therapeutics, cellular therapies and targeted drug-delivery technologies, with research and development centered primarily in the United States. Sorrento’s development programs have included immuno-oncology and chimeric antigen receptor T-cell (CAR-T) therapies, as well as its Sofusa lymphatic drug-delivery platform. The company has also developed resiniferatoxin (RTX), an investigational non-opioid treatment designed to target severe, chronic pain. Other programs have addressed solid tumors, hematologic cancers and infectious diseases, including COVID-19-related diagnostics and therapeutics. Founded in 2009 and headquartered in San Diego, California, Sorrento has operated primarily as a clinical-stage biotechnology company rather than a commercial pharmaceutical business. Dr. Henry Ji, a co-founder, has historically served as chairman and chief executive officer. Sorrento filed for Chapter 11 bankruptcy protection in 2023, and its securities have since undergone significant changes from their former Nasdaq listing.View Sorrento Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
